BAYLOR RESEARCH INSTITUTE

Ultragenyx Pharmaceutical Inc. (RARE) focuses on novel treatments for rare genetic diseases, with products like Crysvita and Mepsevii. It collaborates globally and reported a market cap of $4.031B, with a YTD return of 3.26% as of January 8, 2025.